title: Hepatitis C virus (HCV) genotype analysis in apparently healthy anti-HCV-positive Parisian blood donors.
abstract: BACKGROUND
  As only a few studies have examined the prevalence of various hepatitis C virus (HCV) subtypes in blood donors, information about the variability and route of infection in apparently healthy persons is limited.
  
  
  METHODS
  Blood donations collected at a large Parisian hospital (52,441) were investigated for antibodies to HCV. Serum samples were screened with an enzyme immunoassay. All HCV-positive donations were retested with a second enzyme immunoassay and confirmed by immunoblot. The HCV genotype was determined for all polymerase chain reaction-positive subjects. Untypable genotypes were sequenced in the NS5B region.
  
  
  RESULTS
  In total, 83 (0.26%) blood donors were anti-HCV positive. Men (0.34%) were significantly more likely to be infected (p < 0.001) than women (0.19%). Prevalence rates in men between 20 and 39 years of age were higher than those in similar women (p = 0.01), but greater in women aged from 50 to 65 years (p = 0.05). Fifty-five sera were viremic, of which 49 could be genotyped by a line probe assay. One new HCV type 1 subtype and three new HCV type 2 subtypes were discovered. In total, 28, 10, 11, 5, and 1 serum samples were grouped into HCV types 1 through 5, respectively, involving a total of 13 subtypes. The mean age of HCV type 2-infected donors was 42 +/- 11 years, but that for type 3-infected subjects was only 30 +/- 4 years (p = 0.0048). Forty-nine subjects showed elevated alanine aminotransferase levels; 39 (80%) of these subjects were viremic (p < 0.05).
  
  
  CONCLUSIONS
  Among the sampled population, an HCV prevalence rate of 0.26 percent was found, with the five most common European genotypes causing the infections. Four new subtypes were discovered. Correlation between genotype and risk factors was not apparent, but links with age, sex, and ethnic origin emerged.
authors.affiliation: Department of Nucleic Acid Chemistry, Innogenetics NV, University of Ghent, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Stuyver
authors.forename: C
authors.initials: C
authors.lastname: Fretz
authors.forename: C
authors.initials: C
authors.lastname: Esquivel
authors.forename: A
authors.initials: A
authors.lastname: Boudifa
authors.forename: D
authors.initials: D
authors.lastname: Jaulmes
authors.forename: N
authors.initials: N
authors.lastname: Azar
authors.forename: F
authors.initials: F
authors.lastname: Lunel
authors.forename: G
authors.initials: G
authors.lastname: Leroux-Roels
authors.forename: G
authors.initials: G
authors.lastname: Maertens
authors.forename: J J
authors.initials: JJ
authors.lastname: Fournel
mesh_terms: D000328:Adult; D000368:Aged; D001782:Blood Donors; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics*; D006526:Hepatitis C / Q000453:epidemiology / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008875:Middle Aged; D010297:Paris / Q000453:epidemiology; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral